Primary Category:
Treatment Protocols
Disease Category:
Hodgkin Lymphoma, Lymphoma
Status:
Closed
A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
NCT#01896999
E4412 is permanently closed to accrual effective June 15, 2021.
